(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with centra
Source link
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…
Birlasoft share price fell over 6 per cent to hit a 52-week low of ₹472.40…
Prime Minister Narendra Modi has embarked on a significant two-nation visit, starting with France from…
The inflows into mutual fund equity schemes dipped four per cent last month to ₹39,688…
Ashok Leyland, the Indian flagship of the Hinduja Group announced its December quarter performance today,…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…